NO20072466L - Fremgangsmate for a forhindre og behandle strukturendring i luftveier og pulmonal inflammasjon ved a anvende A2B-adenosinreseptorantagonister - Google Patents

Fremgangsmate for a forhindre og behandle strukturendring i luftveier og pulmonal inflammasjon ved a anvende A2B-adenosinreseptorantagonister

Info

Publication number
NO20072466L
NO20072466L NO20072466A NO20072466A NO20072466L NO 20072466 L NO20072466 L NO 20072466L NO 20072466 A NO20072466 A NO 20072466A NO 20072466 A NO20072466 A NO 20072466A NO 20072466 L NO20072466 L NO 20072466L
Authority
NO
Norway
Prior art keywords
receptor antagonists
preventing
adenosine receptor
respiratory
structural change
Prior art date
Application number
NO20072466A
Other languages
English (en)
Norwegian (no)
Inventor
Luiz Belardinelli
Dewan Zeng
Michael R Blackburn
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of NO20072466L publication Critical patent/NO20072466L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NO20072466A 2004-10-15 2007-05-14 Fremgangsmate for a forhindre og behandle strukturendring i luftveier og pulmonal inflammasjon ved a anvende A2B-adenosinreseptorantagonister NO20072466L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61943904P 2004-10-15 2004-10-15
PCT/US2005/036950 WO2006044610A1 (fr) 2004-10-15 2005-10-14 Procede de prevention et de traitement du remodelage des voies respiratoires et de l'inflammation pulmonaire par le biais d'antagonistes du recepteur d'adenosine a2b

Publications (1)

Publication Number Publication Date
NO20072466L true NO20072466L (no) 2007-05-14

Family

ID=35677798

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072466A NO20072466L (no) 2004-10-15 2007-05-14 Fremgangsmate for a forhindre og behandle strukturendring i luftveier og pulmonal inflammasjon ved a anvende A2B-adenosinreseptorantagonister

Country Status (13)

Country Link
US (2) US20060159627A1 (fr)
EP (2) EP1799221A1 (fr)
JP (2) JP2008516969A (fr)
KR (1) KR20070063548A (fr)
CN (1) CN101039677A (fr)
AU (1) AU2005295654B2 (fr)
CA (1) CA2583986A1 (fr)
IL (1) IL182493A0 (fr)
MX (1) MX2007004373A (fr)
NO (1) NO20072466L (fr)
NZ (2) NZ589657A (fr)
RU (1) RU2391103C2 (fr)
WO (1) WO2006044610A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
AU2001238665A1 (en) * 2000-02-23 2001-09-03 Cv Therapeutics, Inc. Method of identifying partial agonists of the a2a receptor
AU2003259264A1 (en) * 2002-07-29 2004-02-16 Cv Therapeutics, Inc. Myocardial perfusion imaging using a2a receptor agonists
AU2004268964B2 (en) * 2003-08-25 2010-03-11 Allergan Sales, Llc Substituted 8-heteroaryl xanthines
CN101076343A (zh) * 2004-10-20 2007-11-21 Cv医药有限公司 A2a腺苷受体激动剂的应用
WO2006091936A2 (fr) 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Procedes permettant d'effectuer la synthese de xanthines a substitution cycloalkyle dissymetrique
US7618962B2 (en) * 2005-02-25 2009-11-17 Pgx Health, Llc Pyrazolyl substituted xanthines
US7579348B2 (en) * 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
EP2301937A1 (fr) * 2005-06-16 2011-03-30 Cv Therapeutics, Inc. Prodrogues d'antagonistes de récepteurs A2b de l'adénosine
WO2007084486A2 (fr) * 2006-01-13 2007-07-26 Battelle Memorial Institute Modèle animal permettant d'évaluer des maladies associées à copd
EP2581381A3 (fr) 2006-02-03 2013-10-30 Gilead Sciences, Inc. Procédé de préparation d'un agoniste du récepteur A2A-adénosine et ses polymorphes
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
WO2008028140A1 (fr) * 2006-09-01 2008-03-06 Cv Therapeutics, Inc. Méthodes et compositions permettant d'augmenter la tolérabilité de patients pendant des méthodes d'imagerie myocardique
JP2011502101A (ja) * 2006-09-29 2011-01-20 ギリアード・パロ・アルト・インコーポレイテッド 肺疾患の病歴を有する患者における心筋画像化法
CA2673653A1 (fr) * 2007-01-03 2008-07-17 Cv Therapeutics, Inc. Imagerie de perfusion myocardique
CN102015712A (zh) * 2008-03-26 2011-04-13 阿德维纳斯治疗私人有限公司 作为腺苷受体拮抗剂的杂环化合物
WO2010037122A1 (fr) * 2008-09-29 2010-04-01 Gilead Palo Alto, Inc. Combinaisons d'agent de régulation de la fréquence cardiaque et d'antagoniste de récepteur a-2-alpha utilisées dans des procédés de tomographie à détecteurs multiples assistée par ordinateur
US8859566B2 (en) * 2009-03-13 2014-10-14 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
CN103237548A (zh) * 2010-06-30 2013-08-07 吉利德科学股份有限公司 A2b腺苷受体拮抗剂用于治疗肺高血压的应用
AR085942A1 (es) 2011-04-07 2013-11-06 Gilead Sciences Inc Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
EP3224279B1 (fr) * 2014-11-24 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Traitement des exacerbations aiguës de la maladie pulmonaire obstructive chronique par l'antagonisme de l' il- 20r .
ES2580702B1 (es) 2015-02-25 2017-06-08 Palobiofarma, S.L. Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina
CA3093234A1 (fr) 2018-03-05 2019-09-12 Teon Therapeutics, Inc. Antagonistes du recepteur de l'adenosine et leurs utilisations
MX2023002676A (es) * 2020-09-04 2023-05-10 Teon Therapeutics Inc Cocristales de un antagonista del receptor de adenosina a2b.

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5854081A (en) 1996-06-20 1998-12-29 The University Of Patent Foundation Stable expression of human A2B adenosine receptors, and assays employing the same
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6545002B1 (en) 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
US6815446B1 (en) 1999-08-31 2004-11-09 Vanderbilt University Selective antagonists of A2B adenosine receptors
MXPA02002262A (es) * 1999-08-31 2002-09-30 Univ Vanderbilt Antagonistas selectivos de los receptores adenosina a2b.
EP1255550A2 (fr) 2000-02-17 2002-11-13 Cv Therapeutics, Inc. Procede d'identification et d'utilisation d'antagonistes du recepteur d'adenosine a2b pour agir sur la proliferation cellulaire d'un mammifere
US6387913B1 (en) * 2000-12-07 2002-05-14 S. Jamal Mustafa Method of treating airway diseases with combined administration of A2B and A3 adenosine receptor antagonists
US20030235555A1 (en) * 2002-04-05 2003-12-25 David Shealey Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
US7317017B2 (en) 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20080318983A1 (en) 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
US7304070B2 (en) 2001-11-09 2007-12-04 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
CN100467469C (zh) * 2001-11-09 2009-03-11 Cv医药有限公司 A2b腺苷受体拮抗剂
US7125993B2 (en) 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6933298B2 (en) * 2001-12-08 2005-08-23 Aventis Pharma Deutschland Gmbh Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases
WO2003053366A2 (fr) * 2001-12-20 2003-07-03 Osi Pharmaceuticals, Inc. Composes pyrimidine antagonistes selectifs des recepteurs a2b, leur synthese et leur utilisation
ES2229928B1 (es) 2003-10-02 2006-07-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirimidin-2-amina.
MXPA06004789A (es) 2003-10-31 2006-07-03 Cv Therapeutics Inc Antagonistas del receptor de adenosina a2b.
SI1789053T1 (sl) 2004-09-01 2012-09-28 Gilead Sciences Inc Postopek celjenja rane z uporabo antagonistov A2B adenozinskih receptorjev
EP2301937A1 (fr) 2005-06-16 2011-03-30 Cv Therapeutics, Inc. Prodrogues d'antagonistes de récepteurs A2b de l'adénosine
US7795268B2 (en) 2006-03-17 2010-09-14 Gilead Palo Alto, Inc. Method of treating hepatic disease using A2B adenosine receptor antagonists

Also Published As

Publication number Publication date
JP2012056965A (ja) 2012-03-22
CA2583986A1 (fr) 2006-04-27
IL182493A0 (en) 2007-09-20
KR20070063548A (ko) 2007-06-19
RU2007117907A (ru) 2008-11-20
MX2007004373A (es) 2007-08-08
NZ589657A (en) 2012-06-29
WO2006044610A1 (fr) 2006-04-27
AU2005295654A1 (en) 2006-04-27
NZ554485A (en) 2010-12-24
RU2391103C2 (ru) 2010-06-10
EP1799221A1 (fr) 2007-06-27
AU2005295654B2 (en) 2011-04-14
CN101039677A (zh) 2007-09-19
EP2311462A1 (fr) 2011-04-20
US8466129B2 (en) 2013-06-18
JP2008516969A (ja) 2008-05-22
US20100105706A1 (en) 2010-04-29
US20060159627A1 (en) 2006-07-20

Similar Documents

Publication Publication Date Title
NO20072466L (no) Fremgangsmate for a forhindre og behandle strukturendring i luftveier og pulmonal inflammasjon ved a anvende A2B-adenosinreseptorantagonister
BR0110946A (pt) Nova composição
WO2006117299A3 (fr) Formes cristallines de bromure de tiotropium
NO341523B1 (no) Benzoimidazol-2-ylpyrimidiner og -pyraziner som modulatorer av histamin H4-reseptoren, farmasøytisk sammensetning samt anvendelse
SE0200356D0 (sv) Novel use
NO20070387L (no) Kvarternaere salt-CCR2-antagonister
DK1845994T3 (da) Kombination af methylxanthinforbindelser og steroider til at behandle kroniske luftvejssygdomme
DK1718336T3 (da) Ny kombination af anticholinergikum og beta-mimetika til behandling af luftvejssygdomme
WO2010037066A3 (fr) Unités posologiques d'acide 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-méthylpyridin-2-yl)benzoïque
WO2010094720A3 (fr) Polypeptides, domaines variables d'anticorps, et antagonistes améliorés, tous étant des anti-tnfr1
NO20062569L (no) Nye krystallinske anhydrider med antikolinergisk effekt
MX2009001534A (es) Preparacion de (r,r)-fenoterol y analogos de (r,r)- o (r,s)-fenoterol y su uso en el tratamiento de insuficiencia cardiaca congestiva.
EA200801520A1 (ru) Химерные и гуманизированные антитела против человеческого интерлейкина-13 (il-13)
EA200970158A1 (ru) Производные хинуклидина в качестве антагонистов м3
WO2009019598A3 (fr) Thérapie par inhalation pour des troubles respiratoires
WO2004043392A3 (fr) Inhibiteurs de synthese de la mucine
ATE378051T1 (de) Nicotinrezeptor-agonisten zur behandlung von entzündlichen lungenerkrankungen
NO20081480L (no) Kombinasjon av forbindelser som kan brukes ved behandling av respiratoriske sykdommer, spesielt kronisk obstruktiv pulmonaer sykdom (COPD) og astma
CY1108420T1 (el) Προτοτυπο τιοτροπιουχο κονιωδες σκευασμα για εισπνοη
MY143364A (en) Method for producing tiotropium salts
WO2004113286A3 (fr) Inhibiteurs de la synthese des mucines
SE9900834D0 (sv) Novel combination
NO20081483L (no) Kombinasjon av forbindelser som kan brukes ved behandling av respiratoriske sykdommer, spesielt kronisk obstruktiv pulmonaer sykdom (COPD) og astma
MX2010008685A (es) Farmacoforos duales-antagonistas muscarinicos de pde4.
MXPA04007294A (es) Composicion para inhalacion.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application